Literature DB >> 11420676

Characterization of germline TP53 splicing mutations and their genetic and functional analysis.

J M Varley1, C Attwooll, G White, G McGown, M Thorncroft, A M Kelsey, M Greaves, J Boyle, J M Birch.   

Abstract

Germline TP53 splicing mutations have been described infrequently (>2%) in the literature, however in a series of 40 patients and families identified by our group in which there are germline TP53 mutations, seven affect splicing (18%). The low figure reported in the literature might reflect the method of mutation detection, which in many studies does not include all splice junctions. These data indicate that a significant proportion of TP53 germline mutations are currently unrecognized. We have carried out detailed studies of the effects of the different mutations on splicing, and see distinct variations in the effects of the same mutation in different patients. Furthermore we have identified the usage of a non-consensus splice donor site in four families with an intron 4 splice donor mutation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11420676     DOI: 10.1038/sj.onc.1204369

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  19 in total

1.  Li-fraumeni syndrome.

Authors:  David Malkin
Journal:  Genes Cancer       Date:  2011-04

2.  Polymorphism in exon 4 of TP53 gene associated to HPV 16 and 18 in Mexican women with cervical cancer.

Authors:  Patricia Piña-Sánchez; Dulce María Hernández-Hernández; Lucia Taja-Chayeb; Ricardo M Cerda-Flores; Ana Lilia González-Herrera; Carlos Rodea-Avila; Teresa Apresa-García; Patricia Ostrosky-Wegman; Guelaguetza Vázquez-Ortíz; Patricia Mendoza-Lorenzo; Alfonso Dueñas-González; Mauricio Salcedo
Journal:  Med Oncol       Date:  2010-07-27       Impact factor: 3.064

3.  Clinical and Functional Significance of TP53 Exon 4-Intron 4 Splice Junction Variants.

Authors:  Emilia M Pinto; Kara N Maxwell; Hadeel Halalsheh; Aaron Phillips; Jacquelyn Powers; Suzanne MacFarland; Michael F Walsh; Kelsey Breen; Maria N Formiga; Richard Kriwacki; Kim E Nichols; Roya Mostafavi; Jinling Wang; Michael R Clay; Carlos Rodriguez-Galindo; Raul C Ribeiro; Gerard P Zambetti
Journal:  Mol Cancer Res       Date:  2021-10-21       Impact factor: 6.333

4.  Higher-than-expected population prevalence of potentially pathogenic germline TP53 variants in individuals unselected for cancer history.

Authors:  Kelvin César de Andrade; Lisa Mirabello; Douglas R Stewart; Eric Karlins; Roelof Koster; Mingyi Wang; Susan M Gapstur; Mia M Gaudet; Neal D Freedman; Maria Teresa Landi; Nathanaël Lemonnier; Pierre Hainaut; Sharon A Savage; Maria Isabel Achatz
Journal:  Hum Mutat       Date:  2017-09-21       Impact factor: 4.878

5.  Variable population prevalence estimates of germline TP53 variants: A gnomAD-based analysis.

Authors:  Kelvin C de Andrade; Megan N Frone; Talia Wegman-Ostrosky; Payal P Khincha; Jung Kim; Amina Amadou; Karina M Santiago; Fernanda P Fortes; Nathanaël Lemonnier; Lisa Mirabello; Douglas R Stewart; Pierre Hainaut; Luiz P Kowalski; Sharon A Savage; Maria I Achatz
Journal:  Hum Mutat       Date:  2018-11-19       Impact factor: 4.878

6.  TP53 mutations in Korean patients with non-small cell lung cancer.

Authors:  Eung Bae Lee; Guang Jin; Shin Yup Lee; Ji Young Park; Min Jung Kim; Jin Eun Choi; Hyo Sung Jeon; Seung Ick Cha; Sukki Cho; Chang Ho Kim; Tae-In Park; Tae Hoon Jung; Ji-Woong Son; Jae Yong Park
Journal:  J Korean Med Sci       Date:  2010-04-16       Impact factor: 2.153

7.  Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers.

Authors:  Simone Hettmer; Natasha M Archer; Gino R Somers; Ana Novokmet; Amy J Wagers; Lisa Diller; Carlos Rodriguez-Galindo; Lisa A Teot; David Malkin
Journal:  Cancer       Date:  2013-12-30       Impact factor: 6.860

8.  Inherited germline TP53 mutation encodes a protein with an aberrant C-terminal motif in a case of pediatric adrenocortical tumor.

Authors:  Emilia M Pinto; Raul C Ribeiro; Gad B Kletter; John P Lawrence; Jesse J Jenkins; Jinling Wang; Sheila Shurtleff; Lisa McGregor; Richard W Kriwacki; Gerard P Zambetti
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

9.  Biased exon/intron distribution of cryptic and de novo 3' splice sites.

Authors:  Jana Královicová; Mikkel B Christensen; Igor Vorechovský
Journal:  Nucleic Acids Res       Date:  2005-09-01       Impact factor: 16.971

10.  Aberrant 3' splice sites in human disease genes: mutation pattern, nucleotide structure and comparison of computational tools that predict their utilization.

Authors:  Igor Vorechovský
Journal:  Nucleic Acids Res       Date:  2006-09-08       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.